Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
neuroendocrine tumor treatment
market4 mentionslast seen Nov 9, 2026
Relationships 1
Relationship
bamzireotide navoxetanapplies toneuroendocrine tumor treatment
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- filingSEC EDGARNov 9, 2026Perspective Therapeutics, Inc. 8-K: Item 2.02: Results of Operations and Financial Condition; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
European orphan medicinal product designation granted in July 2026 for the treatment of gastroenteropancreatic (GEP)-NETs
- filingSEC EDGARNov 6, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors)
- filingSEC EDGAROct 23, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
[212Pb]VMT-α-NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors
- filingSEC EDGAROct 8, 2026Perspective Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors)